Viridian Therapeutics IncDE
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
VRDN$30.19+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $99,594 | $102,827 |
| Short-term investments | 617,990 | 374,543 |
| Prepaid expenses and other current assets (including related party of $800 and $— as of December 31, 2024 and 2023, respectively) | 20,877 | 9,006 |
| Unbilled revenue - related party | — | 102 |
| Total current assets | 738,461 | 486,478 |
| Property and equipment, net | 1,236 | 1,672 |
| Operating lease right-of-use asset | 2,205 | 1,670 |
| Other assets | 501 | 604 |
| Total assets | $742,403 | $490,424 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,143 | $2,239 |
| Accrued liabilities and other (including related party of $0 and $374 as of December 31, 2024 and 2023, respectively) | 45,443 | 24,108 |
| Current portion of deferred revenue - related party | 288 | 288 |
| Total current liabilities | 47,874 | 26,635 |
| Long-term debt, net | 20,582 | 20,205 |
| Deferred revenue - related party | 284 | 573 |
| Other liabilities | 2,024 | 989 |
| Total liabilities | 70,764 | 48,402 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, series A non-voting convertible preferred stock, $0.01 par value; 435,000 shares authorized; 134,864 and 172,435 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 61,188 | 78,235 |
| Preferred stock, series B non-voting convertible preferred stock, $0.01 par value; 500,000 shares authorized; 145,160 and 143,522 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 127,697 | 128,281 |
| Common stock, $0.01 par value; 200,000,000 shares authorized; 80,994,046 and 53,986,112 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 810 | 540 |
| Additional paid-in capital | 1,477,811 | 960,536 |
| Accumulated other comprehensive income (loss) | (10) | 338 |
| Accumulated deficit | (995,857) | (725,908) |
| Total stockholders’ equity | 671,639 | 442,022 |
| Total liabilities and stockholders’ equity | $742,403 | $490,424 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.